Results of a phase I open label dose escalation study of intracoronary and intravenous basic fibroblast growth factor (rFGF-2) in patients (Pts) with severe ischemic heart disease: 6 months follow-up

被引：0
|
作者：
Laham, RJ
Chronos, NA
Leimbach, M
Pearlman, JD
Pettigrew, R
Dilsizian, V
Udelson, J
Whitehouse, MJ
Pike, M
Yoshizawa, C
Simons, M
机构：
[1] Beth Israel Deaconess Med Ctr, Boston, MA USA
[2] Atlanta Cardiovasc Res Inst, Atlanta, GA USA
[3] Emory Univ, Atlanta, GA 30322 USA
[4] NIH, Bethesda, MD 20892 USA
[5] New England Med Ctr, Boston, MA 02111 USA
[6] Chiron Corp, Emeryville, CA 94608 USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2000年 / 35卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：73A / 73A
页数：1
相关论文
共 12 条
  • [1] Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: Results of a phase I open-label dose escalation study
    Laham, RJ
    Chronos, NA
    Pike, M
    Leimbach, ME
    Udelson, JE
    Pearlman, JD
    Pettigrew, RI
    Whitehouse, MJ
    Yoshizawa, C
    Simons, M
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (07) : 2132 - 2139
  • [2] Reduction in stress myocardial ischemia by basic fibroblast growth factor (rFGF-2) in severe ischemic heart disease
    Udelson, JE
    Dilsizian, V
    Laham, RJ
    Chronos, NA
    Vansant, J
    Whitehouse, MJ
    Pike, M
    Yoshizawa, C
    Simons, M
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (02) : 74A - 74A
  • [3] High-Dose Plasmid-Mediated VEGF Gene Transfer is Safe in Patients With Severe Ischemic Heart Disease (GENESIS-I). A Phase I, Open-Label, Two-Year Follow-up Trial
    Favaloro, Liliana
    Diez, Mirta
    Mendiz, Oscar
    Vera Janavel, Gustavo
    Valdivieso, Leon
    Ratto, Roxana
    Garelli, Guillermo
    Salmo, Fabian
    Criscuolo, Marcelo
    Bercovich, Andres
    Crottogini, Alberto
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2013, 82 (06) : 899 - 906
  • [4] Angiogenesis protein therapy with human fibroblast growth factor (fgf-1): results of a phase I open label, dose escalation study in subjects with CAD not eligible for PCI or CABG
    Wagoner, Lynne E.
    Merrill, Walter
    Jacobs, Jack
    Conway, Ginger
    Boehmer, John
    Thomas, Kenneth
    Stegmann, Thomas
    CIRCULATION, 2007, 116 (16) : 443 - 443
  • [5] Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)-SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results
    Moreno Garcia, V.
    Oh, D-Y.
    Ryu, M. H.
    Calvo, E.
    Garralda, E.
    Chung, W-P.
    Bai, L-Y.
    Rojas Laimito, K. I.
    Yildirim, O.
    Masciari, S.
    Mi, G.
    Wang, L.
    Kanlikilicer, P.
    Buday, B.
    Rharbaoui, F.
    Abbadessa, G.
    Dumbrava, E. E.
    ANNALS OF ONCOLOGY, 2024, 35 : S518 - S518
  • [6] Mature Results of a Phase 1-2 Open-Label, Dose-Escalation Study of Intravenous SNS01-T in Patients (pts) with Relapsed or Refractory B-Cell Malignancies
    Siegel, David S.
    McDonald, Andrew
    Novitzky, Nicolas
    Bensinger, William
    Craig, Michael
    van Rhee, Frits
    Gutierrez, Martin
    Libby, Edward N.
    Thompson, John
    Bexon, Alice S.
    Barranco, Charles
    Taylor, Catherine A.
    Dondero, Richard
    Browne, Leslie J.
    Kurman, Michael R.
    Lust, John A.
    BLOOD, 2014, 124 (21)
  • [7] Updated Follow-up of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Patients with Severe Hemophilia A
    Konkle, Barbara A.
    Stine, Kimo
    Visweshwar, Nathan
    Harrington, Thomas J.
    Leavitt, Andrew D.
    Giermasz, Adam
    Arkin, Steven
    Di Russo, Gregory
    Snyder, Ashley
    Woolfson, Adrian
    Rouy, Didier
    BLOOD, 2019, 134
  • [8] A phase I, open-label dose-escalation trial of weekly (qw) BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking Nanobody, in patients (pts) with advanced/metastatic solid tumors.
    Isambert, Nicolas
    Elez, Elena
    Zanetta, Sylvie
    Matos, Ignacio
    Nazabadioko, Serge
    Xue, Wenqiong
    Carriere, Philippe
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and I in a 4 week on, 2 week off schedule in patients with advanced solid tumors.
    Eskens, F. A.
    Planting, A.
    Van Doorn, L.
    Isoe, T.
    Hayashi, K.
    Hussain, S.
    Ekman, L.
    Burger, H.
    Verweij, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 87S - 87S
  • [10] The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study
    L R Molife
    P C Fong
    L Paccagnella
    A H M Reid
    H M Shaw
    L Vidal
    H-T Arkenau
    V Karavasilis
    T A Yap
    D Olmos
    J Spicer
    S Postel-Vinay
    D Yin
    A Lipton
    L Demers
    K Leitzel
    A Gualberto
    J S de Bono
    British Journal of Cancer, 2010, 103 : 332 - 339
12